Weiss Multi-Strategy Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-31,061	Closed	-$717K	–	926
2020 Q4	$717K	Buy	+31,061	New	+$394K	0.01%	523

Weiss Multi-Strategy Advisers's PRVL Position: Q1 2021 in Review

Weiss Multi-Strategy Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 31,061 shares — an estimated $717K sold.

Weiss Multi-Strategy Advisers first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $717K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Weiss Multi-Strategy Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 31,061 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $717K.
Weiss Multi-Strategy Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Weiss Multi-Strategy Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $717K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2021, filed 14 May 2021.